To assess whether moderate-to-severe CKD is a treatment modifier for benefit or harm in patients randomly allocated to 24-month versus 6-month DAPT.
Impact of chronic kidney disease on 2-year clinical outcomes in patients treated with 6-month or 24-month DAPT duration: An analysis from the PRODIGY trial / Gargiulo, Giuseppe; Santucci, Andrea; Piccolo, Raffaele; Franzone, Anna; Ariotti, Sara; Baldo, Andrea; Esposito, Giovanni; Moschovitis, Aris; Windecker, Stephan; Valgimigli, Marco. - In: CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS. - ISSN 1522-1946. - (2017). [10.1002/ccd.26921]
Impact of chronic kidney disease on 2-year clinical outcomes in patients treated with 6-month or 24-month DAPT duration: An analysis from the PRODIGY trial
GARGIULO, GIUSEPPE;PICCOLO, RAFFAELE;FRANZONE, ANNA;ESPOSITO, GIOVANNI;
2017
Abstract
To assess whether moderate-to-severe CKD is a treatment modifier for benefit or harm in patients randomly allocated to 24-month versus 6-month DAPT.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
